Abstract
Shares in WuXi Biologics surged 39% on June 13, its first day of trading on the Hong Kong Stock Exchange. The company, a Chinese contract researcher and manufacturer of antibody-drug conjugates and other biological drugs, raised more than $500 million from its initial public offering. WuXi Biologics is a subsidiary of the giant contract research firm WuXi AppTec, which delisted from the New York Stock Exchange in 2015 after a management buyout. At the time, WuXi’s Chair Ge Li said he did not intend to relist the company on a stock exchange in China.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
